Novo Nordisk Stock: Is It Still a Smart Buy?

Much like the long-term users of its most popular product, Novo Nordisk's (NVO 0.69%) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete.I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's ...